Stock PHARMACARE DAR AL-SHIFA PHARMACEUTICALS COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dar Al-Shifa Pharmaceuticals Company

Equities

PHARMACARE

PS2014112861

Pharmaceuticals

End-of-day quote Palestine Exchange
Other stock markets
 18:00:00 2022-12-18 EST 		5-day change 1st Jan Change
3.35 USD +4.69% Intraday chart for Dar Al-Shifa Pharmaceuticals Company -.--% -.--%
2022 Dar Al-Shifa Pharmaceuticals Company Reports Earnings Results for the Full Year Ended December 31, 2021 CI
2021 Dar Al-Shifa Pharmaceuticals Company Reports Earnings Results for the Nine Months Ended September 30, 2021 CI

Valuation

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Capitalization 1 30.55 30.89 30.89 30.08 30.08 28.36
Enterprise Value (EV) 1 42.76 45.3 42.42 41.54 52.92 49.39
P/E ratio 20.4 x 29.9 x 11.6 x 18 x 10.5 x 5.83 x
Yield 2.22% 2.19% - - 2.86% 3.03%
Capitalization / Revenue 1.63 x 1.56 x 1.75 x 1.74 x 1.31 x 0.92 x
EV / Revenue 2.28 x 2.29 x 2.4 x 2.4 x 2.3 x 1.61 x
EV / EBITDA 14 x 23.6 x 7.69 x 9.69 x 9.06 x 5.34 x
EV / FCF -10.9 x 37.6 x 92.9 x 20.3 x -41.2 x -80.3 x
FCF Yield -9.19% 2.66% 1.08% 4.93% -2.43% -1.24%
Price to Book 1.15 x 1 x 1.1 x 0.92 x 1.11 x 1.14 x
Nbr of stocks (in thousands) 8,863 8,863 8,863 9,000 9,000 9,000
Reference price 2 3.447 3.485 3.485 3.342 3.342 3.151
Announcement Date 17-08-23 18-08-12 19-09-04 20-05-05 21-12-02 22-09-12
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net sales 1 18.76 19.76 17.7 17.28 23.02 30.71
EBITDA 1 3.053 1.917 5.514 4.287 5.843 9.255
EBIT 1 0.7415 -0.6939 3.769 2.205 3.34 6.904
Operating Margin 3.95% -3.51% 21.3% 12.77% 14.51% 22.48%
Earnings before Tax (EBT) 1 0.7013 0.7391 2.928 2.018 2.49 6.221
Net income 1 1.499 1.034 2.702 1.675 2.857 4.866
Net margin 7.99% 5.23% 15.27% 9.69% 12.41% 15.85%
EPS 2 0.1692 0.1167 0.3002 0.1861 0.3175 0.5407
Free Cash Flow 1 -3.931 1.205 0.4568 2.047 -1.284 -0.6148
FCF margin -20.96% 6.1% 2.58% 11.85% -5.58% -2%
FCF Conversion (EBITDA) - 62.86% 8.29% 47.74% - -
FCF Conversion (Net income) - 116.5% 16.91% 122.2% - -
Dividend per Share 2 0.0764 0.0764 - - 0.0955 0.0955
Announcement Date 17-08-23 18-08-12 19-09-04 20-05-05 21-12-02 22-09-12
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net Debt 1 12.2 14.4 11.5 11.5 22.8 21
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 3.998 x 7.517 x 2.092 x 2.674 x 3.91 x 2.272 x
Free Cash Flow 1 -3.93 1.21 0.46 2.05 -1.28 -0.61
ROE (net income / shareholders' equity) 1.54% 0.34% 9.47% 5.52% 6.19% 20.2%
ROA (Net income/ Total Assets) 0.84% -0.69% 4.47% 2.58% 2.8% 6.3%
Assets 1 178.6 -150.3 60.46 64.94 102.1 77.24
Book Value Per Share 2 2.990 3.500 3.180 3.620 3.020 2.750
Cash Flow per Share 2 0.3200 0.4300 0.0600 0.0300 0.2000 0.1100
Capex 1 2.59 4.55 1.96 1.38 1.96 2.29
Capex / Sales 13.83% 23.02% 11.1% 8.01% 8.53% 7.44%
Announcement Date 17-08-23 18-08-12 19-09-04 20-05-05 21-12-02 22-09-12
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
DAR AL-SHIFA PHARMACEUTICALS COMPANY Stock Dar Al-Shifa Pharmaceuticals Company
-.--% 30.15M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.55% 823B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+42.31% 641B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.83% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.15% 324B
ABBVIE INC. Stock AbbVie Inc.
+7.09% 301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.02% 241B
ROCHE HOLDING AG Stock Roche Holding AG
+1.64% 223B
NOVARTIS AG Stock Novartis AG
+13.66% 218B
AMGEN INC. Stock Amgen Inc.
+7.87% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PHARMACARE Stock
  4. Financials Dar Al-Shifa Pharmaceuticals Company